Your session is about to expire
← Back to Search
Copanlisib for Diffuse Large B-Cell Lymphoma
Study Summary
This trial is studying copanlisib and combination chemotherapy to see how well they work in treating patients with diffuse large B-cell lymphoma or follicular lymphoma that has come back.
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Non-Hodgkin's Lymphoma
- B-Cell Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 24 Patients • NCT02631590Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are new participants still being admitted to this experiment?
"Indeed, the information compiled on clinicaltrials.gov highlights that this medical experiment is in need of enrolment. The trial was first posted on March 31st 2020 and has seen revisions as recent as July 18th 2022. Aspiring participants should note that 21 patients are required across a single site for successful conclusion of the study."
What evidence exists that demonstrates the safety of Copanlisib for patients?
"As this is a Phase 1 clinical trial, which only has scant research on both safety and efficacy, Copanlisib received an assessed score of 1."
What clinical applications is Copanlisib most frequently employed for?
"Copanlisib is often used as a primary treatment option, and has been known to effectively treat ophthalmia, sympathetic disorders, therapeutic interventions, and branch retinal vein occlusions."
Are there other historical experiments that have utilized Copanlisib?
"Currently, there are 2078 ongoing studies into Copanlisib's efficacy. Of these trials, 563 have reached Phase 3 of the trial process with most situated in Majadahonda, Madrid and a total of 95769 participating locations across the world."
How extensive is the participant base for this clinical trial?
"Affirmative. Clinicaltrials.gov data indicates that this medical trial, initially advertised on March 31st 2020, is still recruiting patients. Currently 21 people are needed to be enrolled from one site location."
Share this study with friends
Copy Link
Messenger